Skip to main content

Table 2 Resistance to the drugs composing the World Health Organization shorter MDR-TB regimen

From: Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres

Resistance to amikacin, n (%) 14/123 (11.4)
Resistance to fluoroquinolones, n (%) 29/134 (21.6)
Resistance to ethionamide, n (%) 44/87 (50.6)
Resistance to pyrazinamide, n (%) 64/132 (48.5)
Resistance to ethambutol, n (%) 65/134 (48.5)
Susceptibility to all drugs included, n (%) 16/84 (19.1)
Resistance to all drugs included, n (%) 0/84 (0.0)
Mean (SD) no. of resistances 2 (1.4)
Resistance to pyrazinamide, ethambutol, ethionamide, fluoroquinolones, n (%) 10/86 (11.6)
Resistance to pyrazinamide, ethambutol, ethionamide, kanamycin, n (%) 5/84 (6.0)
Resistance to pyrazinamide, ethambutol, ethionamide, n (%) 25/86 (29.1)
Resistance to pyrazinamide, ethambutol, fluoroquinolones, n (%) 14/132 (10.6)
Resistance to pyrazinamide, ethambutol, kanamycin, n (%) 8/121 (6.6)
Resistance to pyrazinamide, ethambutol, n (%) 47/132 (35.6)